Currently, there are 449.50M common shares owned by the public and among those 442.43M shares have been available to trade.
The company’s stock has a 5-day price change of 1.64% and 7.26% over the past three months. IVZ shares are trading 1.01% year to date (YTD), with the 12-month market performance up to 40.78% higher. It has a 12-month low price of $12.48 and touched a high of $18.79 over the same period. IVZ has an average intraday trading volume of 3.84 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 1.63%, 5.72%, and 11.98% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Invesco Ltd (NYSE: IVZ) shares accounts for 85.72% of the company’s 449.50M shares outstanding.
It has a market capitalization of $8.11B and a beta (3y monthly) value of 1.43. The earnings-per-share (ttm) stands at -$0.75. The company has a debt-to-equity ratio at 0.52. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.52% over the week and 2.48% over the month.
Earnings per share for the fiscal year are expected to increase by 9.71%, and 13.15% over the next financial year.
Looking at the support for the IVZ, a number of firms have released research notes about the stock. Wells Fargo stated their Underweight rating for the stock in a research note on September 12, 2024, with the firm’s price target at $16. Barclays coverage for the Invesco Ltd (IVZ) stock in a research note released on August 27, 2024 offered a Equal Weight rating with a price target of $18. TD Cowen was of a view on January 04, 2024 that the stock is Outperform, while Keefe Bruyette gave the stock Outperform rating on December 14, 2023, issuing a price target of $15.50- $20. BMO Capital Markets on their part issued Market Perform rating on July 10, 2023.
